Compare Stocks: EGRX, DWTX, RYM, and VERU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$1.46 +2.1%	$1.92	$1.28 ▼ $7.20	$49.63M	1.92	59,599 shs	71,079 shs
EGRX Eagle Pharmaceuticals	$0.97 +1.0%	$0.69	$0.00 ▼ $3.00	$23.38M	0.83	7,753 shs	1,389 shs
RYM RYTHM	$19.60 -2.0%	$21.99	$14.00 ▼ $53.65	$42.71M	9.46	14,802 shs	20,957 shs
VERU Veru	$2.51 -1.2%	$2.53	$2.05 ▼ $7.33	$42.80M	-1.21	188,592 shs	104,940 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	0.00%	+7.35%	-38.14%	-2.01%	-79.35%
EGRX Eagle Pharmaceuticals	0.00%	-5.37%	+29.33%	+44.78%	-64.07%
RYM RYTHM	0.00%	-11.03%	-21.73%	-21.58%	-52.36%
VERU Veru	0.00%	-1.18%	-5.28%	-17.97%	-35.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$1.46 +2.1%	$1.92	$1.28 ▼ $7.20	$49.63M	1.92	59,599 shs	71,079 shs
EGRX Eagle Pharmaceuticals	$0.97 +1.0%	$0.69	$0.00 ▼ $3.00	$23.38M	0.83	7,753 shs	1,389 shs
RYM RYTHM	$19.60 -2.0%	$21.99	$14.00 ▼ $53.65	$42.71M	9.46	14,802 shs	20,957 shs
VERU Veru	$2.51 -1.2%	$2.53	$2.05 ▼ $7.33	$42.80M	-1.21	188,592 shs	104,940 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	0.00%	+7.35%	-38.14%	-2.01%	-79.35%
EGRX Eagle Pharmaceuticals	0.00%	-5.37%	+29.33%	+44.78%	-64.07%
RYM RYTHM	0.00%	-11.03%	-21.73%	-21.58%	-52.36%
VERU Veru	0.00%	-1.18%	-5.28%	-17.97%	-35.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DWTX Dogwood Therapeutics	2.00	Hold	$12.00	721.92% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
RYM RYTHM	1.00	Sell	N/A	N/A
VERU Veru	2.33	Hold	$24.50	876.10% Upside

Current Analyst Ratings Breakdown

Latest EGRX, DWTX, RYM, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	RYM RYTHM	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	DWTX Dogwood Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/21/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/6/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.05	$2.43 per share	0.40	N/A	∞
RYM RYTHM	$17.28M	2.47	N/A	N/A	$6.06 per share	3.23
VERU Veru	N/A	N/A	N/A	N/A	$1.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DWTX Dogwood Therapeutics	-$34.26M	-$8.95	N/A	N/A	N/A	N/A	-75.55%	-40.28%	11/5/2026 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	$1.18	0.82	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
RYM RYTHM	-$33.26M	-$10.53	N/A	N/A	N/A	-6.20%	-12.57%	-2.60%	N/A
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	11/26/2026 (Estimated)

Latest EGRX, DWTX, RYM, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	DWTX Dogwood Therapeutics	-$0.14	-$0.34	-$0.20	-$0.34	N/A	N/A
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A
8/4/2026	Q2 2026	RYM RYTHM	N/A	$0.09	N/A	$0.09	N/A	$23.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DWTX Dogwood Therapeutics	N/A	3.89	3.89
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
RYM RYTHM	N/A	0.59	0.56
VERU Veru	N/A	4.42	4.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DWTX Dogwood Therapeutics	9.05%
EGRX Eagle Pharmaceuticals	85.36%
RYM RYTHM	5.98%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
DWTX Dogwood Therapeutics	0.30%
EGRX Eagle Pharmaceuticals	28.90%
RYM RYTHM	3.48%
VERU Veru	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DWTX Dogwood Therapeutics	8	33.99 million	33.89 million	N/A
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
RYM RYTHM	141	2.18 million	2.10 million	N/A
VERU Veru	230	17.05 million	14.63 million	Optionable

EGRX, DWTX, RYM, and VERU Headlines

Recent News About These Companies

Veru (NASDAQ:VERU) Rating Lowered to "Sell" at Wall Street Zen

September 27, 2026 | americanbankingnews.com

Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer

September 8, 2026 | rttnews.com

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant ...

September 8, 2026 | finance.yahoo.com

Veru refocuses sabizabulin on post-daraxonrasib oncology

September 8, 2026 | tipranks.com

Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan

September 8, 2026 | quiverquant.comQ

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

September 8, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | globenewswire.com

Veru (VERU) Q3 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

August 10, 2026 | seekingalpha.com

Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239

August 10, 2026 | quiverquant.comQ

Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline

August 10, 2026 | quiverquant.comQ

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026 | globenewswire.com

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

August 4, 2026 | globenewswire.com

Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update

August 3, 2026 | quiverquant.comQ

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

August 3, 2026 | globenewswire.com

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

July 30, 2026 | globenewswire.com

Veru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesity

July 27, 2026 | quiverquant.comQ

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

July 27, 2026 | globenewswire.com

Palisade's Dan Veru talks his small cap trading playbook

July 12, 2026 | cnbc.com

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, DWTX, RYM, and VERU Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

$1.46 +0.03 (+2.10%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.52 +0.05 (+3.77%)

As of 10/2/2026 07:24 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Eagle Pharmaceuticals NASDAQ:EGRX

$0.97 +0.01 (+1.04%)

As of 10/2/2026 09:59 AM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

RYTHM NASDAQ:RYM

$19.60 -0.40 (-2.00%)

Closing price 10/2/2026 03:54 PM Eastern

Extended Trading

$19.34 -0.26 (-1.30%)

As of 10/2/2026 07:30 PM Eastern

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

Veru NASDAQ:VERU

$2.51 -0.03 (-1.18%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.53 +0.02 (+0.92%)

As of 10/2/2026 07:57 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, DWTX, RYM, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, DWTX, RYM, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, DWTX, RYM, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, DWTX, RYM, and VERU Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Eagle Pharmaceuticals NASDAQ:EGRX

RYTHM NASDAQ:RYM

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EGRX, DWTX, RYM, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EGRX, DWTX, RYM, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EGRX, DWTX, RYM, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, DWTX, RYM, and VERU Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Eagle Pharmaceuticals NASDAQ:EGRX

RYTHM NASDAQ:RYM

Veru NASDAQ:VERU

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools